U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C19H24N2O3
Molecular Weight 328.4055
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LABETALOL

SMILES

CC(CCC1=CC=CC=C1)NCC(O)C2=CC=C(O)C(=C2)C(N)=O

InChI

InChIKey=SGUAFYQXFOLMHL-UHFFFAOYSA-N
InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)

HIDE SMILES / InChI

Molecular Formula C19H24N2O3
Molecular Weight 328.4055
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://www.rxlist.com/trandate-drug.htm

Labetalol is a blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive. It may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. The capacity of labetalol HCl to block alpha receptors in man has been demonstrated by attenuation of the pressor effect of phenylephrine and by a significant reduction of the pressor response caused by immersing the hand in ice-cold water ("cold-pressor test"). Labetalol HCl's beta1-receptor blockade in man was demonstrated by a small decrease in the resting heart rate, attenuation of tachycardia produced by isoproterenol or exercise, and by attenuation of the reflex tachycardia to the hypotension produced by amyl nitrite. Beta2-receptor blockade was demonstrated by inhibition of the isoproterenol-induced fall in diastolic blood pressure. Both the alpha- and beta-blocking actions of orally administered labetalol HCl contribute to a decrease in blood pressure in hypertensive patients. Labetalol HCl consistently, in dose-related fashion, blunted increases in exercise-induced blood pressure and heart rate, and in their double product. The pulmonary circulation during exercise was not affected by labetalol HCl dosing. Single oral doses of labetalol HCl administered to patients with coronary artery disease had no significant effect on sinus rate, intraventricular conduction, or QRS duration. The atrioventricular (A-V) conduction time was modestly prolonged in two of seven patients. In another study, IV labetalol HCl slightly prolonged A-V nodal conduction time and atrial effective refractory period with only small changes in heart rate. The metabolism of labetalol is mainly through conjugation to glucuronide metabolites. These metabolites are present in plasma and are excreted in the urine and, via the bile, into the feces. Approximately 55% to 60% of a dose appears in the urine as conjugates or unchanged labetalol within the first 24 hours of dosing. Labetalol has been shown to cross the placental barrier in humans. Only negligible amounts of the drug crossed the blood-brain barrier in animal studies. Labetalol is approximately 50% protein bound. Neither hemodialysis nor peritoneal dialysis removes a significant amount of labetalol HCl from the general circulation.

CNS Activity

Curator's Comment: Labetalol has been shown to cross the placental barrier in humans. Only negligible amounts of the drug crossed the blood-brain barrier in animal studies.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LABETALOL HYDROCHLORIDE

Approved Use

Labetalol hydrochloride tablets, USP are indicated in the management of hypertension. Labetalol hydrochloride tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
72.4 ng/mL
100 mg 2 times / 2 days steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LABETALOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
571 ng × h/mL
100 mg 2 times / 2 days steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LABETALOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3000 mg single, oral (max)
Highest studied dose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources:
unhealthy, 18-81
n = 32
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-81
Sex: M+F
Population Size: 32
Sources:
Disc. AE: Orthostatic hypotension...
AEs leading to
discontinuation/dose reduction:
Orthostatic hypotension
Sources:
14 g single, oral (max)
Overdose
Dose: 14 g
Route: oral
Route: single
Dose: 14 g
Co-administed with::
alcohol, p.o
Sources:
healthy, 38
n = 1
Health Status: healthy
Age Group: 38
Sex: F
Population Size: 1
Sources:
Disc. AE: Acute renal failure...
AEs leading to
discontinuation/dose reduction:
Acute renal failure
Sources:
1200 mg 2 times / day multiple, oral (total daily dose)
Recommended
unhealthy
400 mg 2 times / day multiple, oral (max)
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
Disc. AE: Cardiac failure...
Other AEs: Hepatocellular injury, Congestive heart failure...
AEs leading to
discontinuation/dose reduction:
Cardiac failure
Other AEs:
Hepatocellular injury (severe, rare)
Congestive heart failure
Sources: Page: p.5
300 mg single, intravenous (total)
Studied dose
Dose: 300 mg
Route: intravenous
Route: single
Dose: 300 mg
Sources: Page: p.14
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.14
AEs

AEs

AESignificanceDosePopulation
Orthostatic hypotension Disc. AE
3000 mg single, oral (max)
Highest studied dose
Dose: 3000 mg
Route: oral
Route: single
Dose: 3000 mg
Sources:
unhealthy, 18-81
n = 32
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-81
Sex: M+F
Population Size: 32
Sources:
Acute renal failure Disc. AE
14 g single, oral (max)
Overdose
Dose: 14 g
Route: oral
Route: single
Dose: 14 g
Co-administed with::
alcohol, p.o
Sources:
healthy, 38
n = 1
Health Status: healthy
Age Group: 38
Sex: F
Population Size: 1
Sources:
Congestive heart failure
400 mg 2 times / day multiple, oral (max)
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
Cardiac failure Disc. AE
400 mg 2 times / day multiple, oral (max)
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
Hepatocellular injury severe, rare
400 mg 2 times / day multiple, oral (max)
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: multiple
Dose: 400 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
PubMed

PubMed

TitleDatePubMed
Labetalol (AH5158), a competitive alpha- and beta-receptor blocking drug, in the management of hypertension.
1976 Aug
Letter: Emergency treatment of hypertensive crisis following clonidine withdrawal.
1976 May 29
Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.
1992 Jul-Aug
Pharmacological effects of an aldehyde type alpha/beta-adrenoceptor blocking agent with vasodilating properties.
2000 Jun
Treating hypertension in women of child-bearing age and during pregnancy.
2001
Drugs in pregnancy. Antihypertensives.
2001 Dec
Comparative hemodynamic effects of urapidil and labetalol after electroconvulsive therapy.
2001 Dec
Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage.
2001 Jul
Monitored anesthesia care using remifentanil and propofol for awake craniotomy.
2001 Jul
A new aspect of view in synthesizing new type beta-adrenoceptor blockers with ancillary antioxidant activities.
2001 Jul
Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage.
2001 Jul 10
Treatment of paroxysmal sympathetic storm with labetalol.
2001 Jun
Low-dose alpha/beta blockade in the treatment of essential hypertension.
2001 Jun
Cardiac phaeochromocytoma presenting with severe hypertension and chest pain.
2001 May
Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient.
2001 May-Jun
Rapid preparation of a patient with pheochromocytoma with labetolol and magnesium sulfate.
2001 Oct
A comparison of atenolol, labetalol, esmolol, and landiolol for altering human neutrophil functions.
2001 Sep
Labetalol decreases cerebral perfusion pressure without negatively affecting cerebral blood flow in hypertensive gravidas.
2002
Factors influencing acute ischaemia-induced renal hypertension in rats.
2002 Dec
Remifentanil provides hemodynamic stability and faster awakening time in transsphenoidal surgery.
2002 Jan
Pheochromocytoma.
2002 Jan-Feb
[Nuclear medicine diagnosis of pheochromocytoma with metaiodobenzylguanidine].
2002 Jul
Shy-Drager syndrome and severe unexplained intraoperative hypotension responsive to vasopressin.
2002 Jul
Effects of hemoconcentration and sympathetic activation on serum lipid responses to brief mental stress.
2002 Jul-Aug
Acute and chronic hypertensive headache and hypertensive encephalopathy.
2002 May
Refractory hypotension during caesarean section following pre-operative administration of anti-hypertensive agents.
2003 Apr
Left ventricular diastolic function in pregnancy-induced hypertension.
2003 Apr
Spectrophotometric determination of labetalol in pharmaceutical preparations and spiked human urine.
2003 Apr
Multiple Bier blocks with labetalol for complex regional pain syndrome refractory to other treatments.
2003 Apr
The effect of remifentanil on seizure duration and acute hemodynamic responses to electroconvulsive therapy.
2003 Apr
Improvement of peak shape and separation performance of beta-blockers in conventional reversed-phase columns using solvent modifiers.
2003 Aug
Managing hypertension in patients with stroke. Are you prepared for labetalol infusion?
2003 Jun
Acute myocardial infarction as a complication of clonidine withdrawal.
2003 Nov
[Posterior reversible encephalopathy syndrome].
2003 Nov-Dec
Clinical review: the management of hypertensive crises.
2003 Oct
Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis.
2003 Oct 25
[Toxicologic analysis of some adrenergic-beta blockers in the diagnosis of intoxications].
2003 Oct-Dec
A survey of Canadian practitioners regarding the management of the hypertensive disorders of pregnancy.
2004
Very low-dose spinal anesthesia for cesarean section in a morbidly obese preeclamptic patient and its potential implications.
2004 Apr
Dexmedetomidine for awake carotid endarterectomy: efficacy, hemodynamic profile, and side effects.
2004 Apr
Simultaneous determination of thirteen beta-blockers and one metabolite by gradient high-performance liquid chromatography with photodiode-array UV detection.
2004 Apr 20
Hyponatremic hypertensive syndrome (HHS) in an 18-month old-child presenting as malignant hypertension: a case report.
2004 Apr 27
In vitro effects of antihypertensive drugs on thromboxane agonist (U46619)-induced vasoconstriction in human internal mammary artery.
2004 Aug
Chiral separation of labetalol stereoisomers in human plasma by capillary electrophoresis.
2004 Feb 20
Periprocedural hypertension: current concepts in management for the vascular surgeon.
2004 Jul-Aug
[Protective effect of alpha beta-blockers on hypertensive target-organ damage].
2004 Mar
Polymeric alkenoxy amino acid surfactants: II. Chiral separations of beta-blockers with multiple stereogenic centers.
2004 Mar
Effect of beta-adrenergic antagonists on bioluminescence control in three species of brittlestars (Echinodermata: Ophiuroidea).
2004 May
[Surgery to save body-packers].
2004 May
Severe hypertension and massive proteinuria in a newborn with renal artery stenosis.
2004 May
Patents

Patents

Sample Use Guides

The recommended initial dosage is 100 mg twice daily whether used alone or added to a diuretic regimen. After 2 or 3 days, using standing blood pressure as an indicator, dosage may be titrated in increments of 100 mg b.i.d. every 2 or 3 days. The usual maintenance dosage of labetalol HCl is between 200 and 400 mg twice daily.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The effects of the alpha-beta-adrenergic antagonist labetalol on the activation of human platelets by adrenaline and other aggregating stimuli have been investigated. Labetalol inhibited platelet aggregation and secretion induced by collagen and the second phase of aggregation caused by ADP, platelet activating factor, adrenaline and ionophore A23187.
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:53:12 GMT 2023
Edited
by admin
on Sat Dec 16 17:53:12 GMT 2023
Record UNII
R5H8897N95
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LABETALOL
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
BENZAMIDE, 2-HYDROXY-5-(1-HYDROXY-2-((1-METHYL-3-PHENYLPROPYL)AMINO)ETHYL)-
Systematic Name English
AH-5158A FREE BASE
Code English
SCH-15719W FREE BASE
Code English
LABETALOL [HSDB]
Common Name English
Labetalol [WHO-DD]
Common Name English
LABETALOL [VANDF]
Common Name English
IBIDOMIDE
Common Name English
labetalol [INN]
Common Name English
LABETALOL [MI]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK547846
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
NDF-RT N0000175556
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
WHO-ATC C07BG01
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
WHO-VATC QC07CG01
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
WHO-VATC QC07BG01
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
WHO-ATC C07CG01
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
WHO-ATC C07AG01
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
WHO-VATC QC07AG01
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
NDF-RT N0000000161
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
NCI_THESAURUS C72900
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL429
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
ECHA (EC/EINECS)
253-258-3
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
WIKIPEDIA
LABETALOL
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
PUBCHEM
3869
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
MERCK INDEX
m6647
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY Merck Index
LACTMED
Labetalol
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
DAILYMED
R5H8897N95
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
MESH
D007741
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
CHEBI
167638
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
IUPHAR
7207
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
SMS_ID
100000083080
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
RXCUI
6185
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY RxNorm
INN
3941
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
CAS
36894-69-6
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
EVMPD
SUB08382MIG
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
FDA UNII
R5H8897N95
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
DRUG CENTRAL
1531
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID2023191
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
HSDB
6537
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
CHEBI
6343
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
NCI_THESAURUS
C29146
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
DRUG BANK
DB00598
Created by admin on Sat Dec 16 17:53:13 GMT 2023 , Edited by admin on Sat Dec 16 17:53:13 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE ISOMER -> PARENT
TARGET -> INHIBITOR
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Ki
Related Record Type Details
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC